Clinical Trial Update: A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TRU-016 in combination with Rituximab and Bendamustine in relapsed indolent B-cell lymphoma; results posted in 2016. The trial assesses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• TRU-016

Snippet

Sponsor: Aptevo Therapeutics | Conditions: B-cell Small Lymphocytic Lymphoma Recurrent | Phase 1 | Status: COMPLETED | Results posted: 2016-10-06